Seed finance and corporate venture capital: Lack of chemistry

Chimica Oggi

Volumn 21, Issue 6, 2003, Pages 87-90

  Aernoudt, Rudy ^a   San José, Amparo ^b  

^a RD   (Belgium)

^b CENTRE FOR EUROPEAN POLICY STUDIES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; EUROPE; FINANCIAL MANAGEMENT; GOVERNMENT; INVESTMENT; POLICY; REVIEW; UNITED STATES;

EID: 0042731609     PISSN: 0392839X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Bannock; Corporate venturing in Europe, 2001
2. M.V.J. Maula; Corporate Venture Capital and the Value-Added for Technology-Based New Firms, Helsinki University of Technology, 2001
3. Ernst & Young; Corporate Venturing, Building Strategic Growth Options, London, 2002
4. D. Rivaud-Danset; Innovation and New Technologies: Corporate Finance and Financial Constraints; University of Reims and CEPN-CNRS (Paris XIII), 2002
5. a. EVCA; Yearbook 2002, 2002
6. b. EVCA; Corporate Venturing European Activity Update 2001, 2002
7. R. Aernoudt; The Role of Big Companies in the 'Think Small First' Philosophy, Sofia-Antipolis, 2002
8. R. Aernoudt; Incubators: Tool for Entrepreneurship?, in Small Business Journal, 2003
9. M. Queen; Government Policy to Stimulate Equity Finance and Investor Readiness, in Venture Capital, 4 (2002)
10. T. Lawton; Missing the Target, in Venture Capital, 4 (2002)